Fellow Eye Changes in Patients with Nonischemic Central Retinal Vein Occlusion: Assessment of Perfused Foveal Microvascular Density and Identification of Nonperfused Capillaries

Alexander Pinhas
Icahn School of Medicine at Mount Sinai

Michael Dubow
New York Icahn School of Medicine at Mount Sinai

Nishit Shah
New York Eye and Ear Infirmary

Eric Cheang
New York Eye and Ear Infirmary

Chun L. Liu
New York Eye and Ear Infirmary of Mount Sinai

See next page for additional authors


This is a non-final version of an article published in final form in Retina, vol. 35, No. 10 (October 2015): 2028-2036. DOI.
Authors

This article is available at e-Publications@Marquette: https://epublications.marquette.edu/bioengin_fac/418
Fellow Eye Changes in Patients with Nonischemic Central Retinal Vein Occlusion: Assessment of Perfused Foveal Microvascular Density and Identification of Nonperfused Capillaries

Alexander Pinhas
Department of Ophthalmology,
New York Eye and Ear Infirmary of Mount Sinai,
Icahn School of Medicine at Mount Sinai,
New York, NY

Michael Dubow
Department of Ophthalmology,
New York Eye and Ear Infirmary of Mount Sinai,
Icahn School of Medicine at Mount Sinai,
New York, NY

Nishit Shah
Department of Ophthalmology,
New York Eye and Ear Infirmary of Mount Sinai,
New York, NY
Eric Cheang
Department of Ophthalmology,
New York Eye and Ear Infirmary of Mount Sinai,
Stuyvesant High School,
New York, NY

Chun L. Liu
Department of Ophthalmology,
New York Eye and Ear Infirmary of Mount Sinai,
New York, NY
Bronx High School of Science,
Bronx, New York

Moataz Razeen
Department of Ophthalmology,
New York Eye and Ear Infirmary of Mount Sinai,
New York, NY
Alexandria Faculty of Medicine, University of Alexandria,
Alexandria, Egypt

Alexander Gan
Department of Ophthalmology,
New York Eye and Ear Infirmary of Mount Sinai,
New York, NY

Rishard Weitz
Department of Ophthalmology,
New York Eye and Ear Infirmary of Mount Sinai,
New York, NY

Yusufu N. Sulai
The Institute of Optics, University of Rochester,
Rochester, NY

Toco Y. Chui
Department of Ophthalmology,
New York Eye and Ear Infirmary of Mount Sinai,
Icahn School of Medicine at Mount Sinai,
New York, NY
Abstract

**Purpose:** Eyes fellow to nonischemic central retinal vein occlusion (CRVO) were examined for abnormalities, which might explain their increased risk for future occlusion, using adaptive optics scanning light ophthalmoscope fluorescein angiography.

**Methods:** Adaptive optics scanning light ophthalmoscope fluorescein angiography foveal microvascular densities were calculated. Nonperfused capillaries adjacent to the foveal avascular zone were identified. Spectral domain optical coherence tomography, ultrawide field fluorescein angiographies, and microperimetry were also performed.

**Results:** Ten fellow eyes of nine nonischemic CRVO and 1 nonischemic hemi-CRVO subjects and four affected eyes of three nonischemic CRVO and one nonischemic hemi-CRVO subjects were imaged. Ninety percent of fellow eyes and 100% of affected eyes demonstrated at least 1 nonperfused capillary compared with 31% of healthy eyes. Fellow eye microvascular density (35 ± 3.6 mm$^{-1}$) was significantly higher than that of affected eyes (25 ± 5.2 mm$^{-1}$) and significantly lower than that of healthy eyes (42 ± 4.2 mm$^{-1}$). Compared with healthy controls, spectral domain optical coherence tomography thicknesses showed no significant difference, whereas microperimetry and 2/9 ultrawide field fluorescein angiography revealed abnormalities in fellow eyes.

**Conclusion:** Fellow eye changes detectable on adaptive optics scanning light ophthalmoscope fluorescein angiography reflect subclinical pathology difficult to detect using conventional imaging technologies. These changes may help elucidate the pathogenesis of nonischemic CRVO and help identify eyes at increased risk of future occlusion.

**Keywords:** adaptive optics, fluorescein angiography, retinal microvasculature, image analysis, central retinal vein occlusion, fellow eye
Central retinal vein occlusion (CRVO) is a significant cause of acquired vision loss with a global prevalence of 0.08%.\(^1\) Although a number of major and minor systemic risk factors have been identified,\(^2–6\) a considerable number of patients with CRVO present without identifiable risk factors. Thus, despite years of research since its first description in 1855,\(^7\) its pathogenesis remains poorly understood.\(^8,9\)

Epidemiologic studies have shown that eyes fellow to unilateral CRVO have a significantly increased risk of developing venous occlusion compared with the general population.\(^10–12\) Previous studies have shown that before any occlusion, these fellow eyes are both structurally\(^13\) and electrophysiologically\(^14\) compromised. These findings suggest that additional study of fellow eyes may elucidate the early pathological changes signaling a future occlusive event.

The purpose of this study was to assess the perfused foveal microvascular density and identify nonperfused capillaries in nonischemic CRVO fellow and affected eyes using adaptive optics scanning light ophthalmoscope fluorescein angiography (AOSLO FA)\(^15\) and to compare the findings with previously published data on 16 healthy controls.\(^16\) Spectral domain optical coherence tomography (SD-OCT), ultrawide field fluorescein angiography (UWFFA), and microperimetry—standard clinical modalities for studying retinal structure and function—were also performed.

**Methods**

**Subject Recruitment**

This study followed the tenets of the Declaration of Helsinki and was approved by the New York Eye and Ear Infirmary Institutional Review Board. Written informed consent was obtained from each participant after the nature, and potential risks of the study were explained. Retrospective chart review was performed to identify subjects for imaging. Inclusion criteria included a best-corrected visual acuity (BCVA) of ≥20/60 with good central fixation, pupil dilation of at least 5 mm, normal anterior segment with clear crystalline lens, clear media, and minimal or no inner retinal edema at the fovea as...
determined using SD-OCT (Heidelberg Spectralis HRA+OCT; Heidelberg Engineering Inc, Heidelberg, Germany). Ten fellow eyes of 9 nonischemic CRVO and 1 superior nonischemic hemi-CRVO subjects (BCVA ≥20/25; mean age: 45 years; range: 27–67; Table 1) and 4 affected eyes of 3 nonischemic CRVO and 1 superior nonischemic hemi-CRVO subjects (BCVA ≥20/25 – 2; mean age: 50 years; range: 39–64; Table 2) were imaged. Medical histories were reviewed and fellow eyes with any preexisting retinopathy were excluded. All subjects underwent a single imaging session. Previously published data from 16 healthy eyes were used for comparison. The 16 healthy adults included 8 men and 8 women with a mean age of 25 years (range: 21–29). They had no significant medical or surgical history with normal ocular examination and intraocular pressures and a BCVA of 20/20 or better in each study eye.

### Table 1. Demographic of Nonischemic CRVO fellow Eye Patients

<table>
<thead>
<tr>
<th>Subject ID</th>
<th>Age and Sex</th>
<th>Medical/Social History</th>
<th>Medications</th>
<th>Family History</th>
<th>Ophthalmic History</th>
<th>Time Since RVO</th>
</tr>
</thead>
<tbody>
<tr>
<td>RR_0161</td>
<td>67-year-old woman</td>
<td>HL, elevated sugars</td>
<td>Lovastatin, Aspirin</td>
<td>Father: HL</td>
<td>CRVO OS</td>
<td>2 years</td>
</tr>
<tr>
<td>RR_0182</td>
<td>55-year-old man</td>
<td>None</td>
<td>None</td>
<td>Mother: HL; father: DM, HTN; brother: DM</td>
<td>CRVO OD</td>
<td>1.5 years</td>
</tr>
<tr>
<td>RR_0235</td>
<td>39-year-old man</td>
<td>None</td>
<td>None</td>
<td>Mother: DM, HTN, HL; 3/7 siblings: DM</td>
<td>Hemi-CRVO OD</td>
<td>7 months</td>
</tr>
<tr>
<td>RR_0239</td>
<td>27-year-old man</td>
<td>0.5 PPD for 5 years, quit 6 years ago.</td>
<td>None</td>
<td>Not taken</td>
<td>CRVO OD</td>
<td>1 week</td>
</tr>
<tr>
<td>RR_0273</td>
<td>46-year-old woman</td>
<td>Sedentary lifestyle None</td>
<td>None</td>
<td>Both parents: DM</td>
<td>CRVO OD</td>
<td>5.5 years</td>
</tr>
<tr>
<td>RR_0289</td>
<td>44-year-old man</td>
<td>Borderline HTN</td>
<td>None</td>
<td>Father: DM</td>
<td>CRVO OD</td>
<td>2 years</td>
</tr>
<tr>
<td>RR_0298</td>
<td>33-year-old woman</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>CRVO OS</td>
<td>4 years</td>
</tr>
<tr>
<td>RR_0299</td>
<td>37-year-old woman</td>
<td>Anemia</td>
<td>Iron</td>
<td>Mother: HTN</td>
<td>CRVO OS</td>
<td>1 year</td>
</tr>
<tr>
<td>RR_0300</td>
<td>50-year-old woman</td>
<td>Heavy drinking (12–24 beers/week). Quit 1 year ago</td>
<td>Multivitamin</td>
<td>Both parents: DM, HTN; sister: DM</td>
<td>CRVO OS</td>
<td>4 years</td>
</tr>
</tbody>
</table>

DM, diabetes mellitus; HL, hyperlipidemia; HTN, hypertension; PPD, packs per day.
Table 2. Demographic of Nonischemic CRVO Affected Eye Patients

<table>
<thead>
<tr>
<th>Subject ID</th>
<th>Age and Sex</th>
<th>Medical History</th>
<th>Medications</th>
<th>Family History</th>
<th>Ophthalmic History</th>
<th>Time Since RVO</th>
<th>Treatment History</th>
<th>BCVA-Affected Eye</th>
</tr>
</thead>
<tbody>
<tr>
<td>RR_0149</td>
<td>43-year-old man</td>
<td>None</td>
<td>None</td>
<td>Heart disease</td>
<td>CRVO OD</td>
<td>5 years</td>
<td>IBI × 2; 2 years*</td>
<td>20/25 + 2</td>
</tr>
<tr>
<td>RR_0151</td>
<td>64-year-old woman</td>
<td>Bipolar disorder</td>
<td>Valproic acid, Risperidone</td>
<td>None</td>
<td>CRVO OS</td>
<td>1.5 years</td>
<td>IBI × 8; 5 months*</td>
<td>20/20</td>
</tr>
<tr>
<td>RR_0182</td>
<td>55-year-old man</td>
<td>None</td>
<td>None</td>
<td>Mother: HL; father: DM, HTN; brother: DM</td>
<td>CRVO OD</td>
<td>1.5 years</td>
<td>IBI × 4; 1 year*</td>
<td>20/25 – 2</td>
</tr>
<tr>
<td>RR_0235</td>
<td>39-year-old man</td>
<td>None</td>
<td>None</td>
<td>Mother: DM, HTN, HL; 3/7 siblings: DM</td>
<td>Hemi-CRVO OD</td>
<td>7 months</td>
<td>IBI × 1; 5 months*</td>
<td>20/20</td>
</tr>
</tbody>
</table>

*Elapsed time between last IBI and AOSLO FA.
DM, diabetes mellitus; HL, hyperlipidemia; HTN, hypertension; IBI, intravitreal bevacizumab injection.

Clinical Imaging

Charts of the 10 fellow eyes were reviewed for intraocular pressure readings, measured with either application tonometry or Tono-Pen (Tono-Pen XL and AVIA; Reichert Inc, New York, NY) near the date of imaging. Before imaging, mydriasis and cycloplegia were induced using 2.5% phenylephrine hydrochloride ophthalmic solution (Bausch & Lomb Inc, Tampa, FL) and 1% tropicamide ophthalmic solution (Akorn Inc, Lake Forest, IL). Axial lengths were measured in all eyes (IOL Master; Carl Zeiss Meditec AG, Jena, Germany) to size the AOSLO image scale in micrometers per pixel using the Emsley schematic eye model.17

Spectral domain optical coherence tomography imaging and analysis

Spectral domain optical coherence tomography imaging was performed on each of the 10 fellow eyes, using 12 radial scans at 15° intervals through the center of the fovea. Each scan spanned 20° and was an average of 9 frames. Each radial scan was manually segmented to delineate the inner limiting membrane, outer plexiform layer/outer nuclear layer interface, and the retinal pigment epithelium/choroid interface. A spline algorithm was used to interpolate between sample points marked on the inner limiting membrane, outer plexiform layer/outer nuclear layer interface, and
retinal pigment epithelium/choroid interface to measure the inner retinal thickness and total retinal thickness (TRT). Inner retinal thickness and TRT each represented means of 144 data points per eye—12 data points per SD-OCT radial scan at 250, 350, 450, 550, 650, and 750 μm radial distance from foveal center in both directions, times 12 SD-OCT radial scans through the foveal center per eye. Then, IRT/TRT ratios were calculated per fellow eye and compared with respective previously acquired data from 16 healthy eyes.

**Microperimetry**

Microperimetry was performed on fellow eyes after AOSLO FA imaging using a Polar 3 pattern of 28 test points, Goldmann Size III stimuli with duration of 200 milliseconds at 1.5-second intervals, and a 4-2 threshold algorithm (OPKO SD-OCT/SLO with add-on Microperimetry module; OPKO, Miami, FL). Previously published data from 169 healthy eyes were used for comparison.18 The 169 healthy adults included 71 men and 98 women with a mean age of 48 years (range: 21–85). They had no significant medical history with normal ocular examination and intraocular pressures and a BCVA of 20/25 or better in each study eye.

**Ultrawide field fluorescein angiography**

All UWFFAs were performed with intravenous fluorescein administration. Patient records were reviewed for recently performed UWFFA (Optos, Marlborough, MA) on the fellow eyes (within 3 years of AOSLO FA imaging). Ultrawide field fluorescein angiography was acquired for patients without previous studies. Late-phase UWFFA images of the fellow eyes were assessed by two retina specialists for abnormalities.

**Adaptive Optics Scanning Light Ophthalmoscope Fluorescein Angiography Imaging and Analysis**

The AOSLO machine was a replica of the one built by Dubra and Sulai,19 modified for AOSLO FA as described by Pinhas et al.15 Adaptive optics scanning light ophthalmoscope fluorescein angiography imaging and image processing were performed as described by Pinhas et al.16
Fluorescein was administered orally for AOSLO FA imaging to allow for a longer imaging window. Simultaneous 1.75° field-of-view infrared (IR) confocal reflectance (790 nm) and fluorescence (488 nm) image sequences were acquired approximately 10 minutes after oral fluorescein administration. The fluorescence channel was focused on the superficial layers of retinal microvasculature, and the IR reflectance channel was focused on the photoreceptors. A square region of approximately 6° × 6° in size centered at the fovea was imaged. A set of images using the IR channel covering a 2.5° × 2.5° region around the fovea focused on the superficial layers of retinal microvasculature was also acquired. All sources were treated as lasers for the purposes of maximum permissible exposure calculations. Light exposure was determined to be 6 times below both the photochemical and thermal maximum permissible exposure limits according to the American National Standards Institute (ANSI) Z136.

Respective registered averaged images with high signal-to-noise ratio were stitched together to create larger IR structural and FA perfusion maps (Adobe Photoshop CS6; Adobe Systems, Inc, San Jose, CA). Comparison of the IR structural with the FA perfusion maps revealed nonperfused capillaries adjacent to the foveal avascular zone (Figure 1, A and B). Circular FA perfusion maps centered on the fovea with a radius of 800 μm were skeletonized in a semiautomated fashion using a custom-developed MATLAB GUI program (Mathworks, Inc, Natick, MA), as previously described. The skeletonized perfusion maps were then divided into equiangular octants and 8 consecutive annuli with a 100-μm radial step-size, creating 64 regions of interest (Figure 2, A–C). Microvascular density was calculated per region of interest, and individual region of interest values were grouped into annulus, octant, and eye means, which were further averaged per study group. In calculating mean microvascular densities per eye, the central 400 μm was excluded to avoid the effect of substantial foveal avascular zone diameter variation across individuals.
Fig. 1. A. Fluorescein angiography perfusion map of RR_0289 fellow eye (left eye), showing foveal avascular zone and surrounding capillaries. B. Corresponding IR structural map. Arrows indicate non-perfused capillaries.

Fig. 2. A. Fluorescein angiography (FA) perfusion map of RR_0289 fellow eye (left eye). B. Corresponding skeletonized FA perfusion map with (C) octant and annulus grid overlay. D. Colorized density contour map. S, superior; SN, superior nasal; N, nasal; IN, inferior nasal; I, inferior; IT, inferior temporal; T, temporal; ST, superior temporal.

A separate algorithm created colorized density contour maps by computing microvascular density within each 16 × 16-μm sampling window with 8-μm overlaps over the skeletonized perfusion maps using the built-in MATLAB function blkproc. These maps provided a more easily interpretable graphic representation of regional...
microvascular density variations across the FA perfusion maps (Figure 2D).

**Results**

Under the assumption of normally distributed variables, IRT/TRT ratios, microperimetry, and microvascular density group averages ± SD values were compared for significant differences using an unpaired 2-tailed $t$-test with a $P$ value of <0.05.

All 10 fellow eyes had intraocular pressures ≤21 mmHg. Spectral domain optical coherence tomography average IRT/TRT ratio of the 10 fellow eyes was lower than that of healthy eyes; however, this difference was not quite statistically significant (0.37 ± 0.04 vs. 0.39 ± 0.04; $t$(24) = 1.2, $P$ = 0.23). Microperimetry average sensitivity of the 10 fellow eyes (17 ± 1.4, range: 12–20 dB) was significantly lower compared with previously reported normative data (18 ± 1.2, range: 13–20 dB)$^{18}$; $t$(177) = 2.5, $P$ = 0.0120. Previous records of UWFFA were available for 7 fellow eye patients within 3 years before AOSLO FA imaging, and UWFFA was acquired within 3 months after AOSLO FA for 2 fellow eye patients. RR_0273 was lost to follow-up before we were able to obtain UWFFA images. On assessment, RR_0235 showed leakage at a terminal branch of the superotemporal arcade and RR_0289 showed a few central and peripheral microaneurysms (Figure 3, A and B). Ultrawide field fluorescein angiography was within normal limits for the rest of the 7/9 fellow eyes.
Fig. 3. Examples of fellow eye angiopathy discovered on ultrawide field fluorescein angiography. A. RR_0235 left eye showed leakage at a terminal branch of the superotemporal arcade. B. RR_0289 left eye showed a few central and peripheral microaneurysms (arrows).

Comparing AOSLO IR structural and FA perfusion maps allowed detection of at least 1 nonperfused capillary segment in 90% of the 10 fellow eyes (Figure 1, A and B) and 100% of the 4 affected eyes, compared with a 31% rate found in the 16 healthy eyes. Average microvascular density ± SD of the 10 fellow eyes was $35 \pm 3.6 \text{mm}^{-1}$ (range: 30–41 mm$^{-1}$), significantly lower than that of the 16 healthy eyes ($42 \pm 4.2 \text{mm}^{-1}$; range: 33–50 mm$^{-1}$; $t(24) = 4.4, P = 0.0002$) and significantly higher than that of the 4 nonischemic CRVO-affected eyes ($25 \pm 5.2 \text{mm}^{-1}$; range: 18–30 mm$^{-1}$; $t(12) = 4.2, P = 0.0013$) (Table 3; Figure 4, A and B). Figures 5 and 6 are 2 examples of FA perfusion and colorized density contour maps, each showing an affected and fellow eye pair compared with a representative healthy eye. The unaffected octants of the nonischemic hemi-CRVO–affected eye resembled fellow eyes in microvascular density values (Table 2; Figure 6).
Fig. 4. A. Scatter plot of microvascular density values of fellow eyes (n = 10), compared with healthy (n = 16) and affected eyes (n = 4). Microvascular density values are presented per eye as averages of annuli 300–800. Black bars indicate group averages. B. An annulus comparison of microvascular densities of the 3 groups. Error bars represent SD. Asterisks indicate significant differences (unpaired t-test with $P < 0.05$) between healthy and fellow eyes (blue asterisks) and affected and fellow eyes (green asterisks) in microvascular densities at a given annulus.

Fig. 5: RR0182-affected eye (nonischemic central retinal vein occlusion in the right eye) and fellow eye (left eye) compared with a healthy control eye, with fluorescein angiography (FA) perfusion maps and corresponding colorized density contour maps. Subject age, sex, eye imaged, and perfused foveal microvascular density (mean of annuli 300–800) appear in the lower left corner of respective FA perfusion maps.
Fig. 6. RR0235-affected eye (nonischemic superior hemiretinal vein occlusion in the right eye) and fellow eye (left eye) compared with a healthy control eye, with fluorescein angiography (FA) perfusion maps and corresponding colorized density contour maps. Subject age, sex, eye imaged, and perfused foveal microvascular density (mean of annuli 300–800) appear in the lower left corner of respective FA perfusion maps.

Table 3. Microvascular Density Results

<table>
<thead>
<tr>
<th>Eyes</th>
<th>Microvascular Density ± SD (mm⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy eyes (n = 16)</td>
<td>42 ± 4.2</td>
</tr>
<tr>
<td>Affected eyes (n = 4)</td>
<td>25 ± 5.2</td>
</tr>
<tr>
<td>Fellow eyes (n = 10)</td>
<td>35 ± 3.6</td>
</tr>
<tr>
<td>Superior hemi-CRVO eye (n = 1)</td>
<td>SN, S, ST 18</td>
</tr>
<tr>
<td></td>
<td>IN, I, IT 34</td>
</tr>
</tbody>
</table>

Fellow eye microvascular densities were significantly lower than the 16 healthy eyes and significantly higher than the 4 affected eyes. Unaffected octants of the nonischemic superior hemi-CRVO-affected eye had density values similar to fellow eyes.

I, inferior; IN, inferior nasal; IT, inferior temporal; N, nasal; S, superior; SN, superior nasal; ST, superior temporal; T, temporal.

Discussion

Spectral domain optical coherence tomography average IRT/TRT ratios were not significantly different between healthy and fellow eyes. Seven of nine of the fellow eyes did not have signs of vascular
compromise on UWFFA. Fellow eye sensitivity on microperimetry was on the lower side of normal but remained within clinically acceptable levels. Adaptive optics scanning light ophthalmoscope fluorescein angiography revealed an increased number of non-perfused capillaries near the foveal avascular zone and decreased perfused foveal microvascular density in fellow eyes, compared with healthy data. Microvascular compromise may directly cause previously documented fellow eye structural and functional abnormalities\textsuperscript{13,14}; however, with the current limited data, the sequence of events remains uncertain.

Using current knowledge of pathophysiology, we attempt to explain why eyes fellow to nonischemic CRVO may show decreased foveal microvascular density. The major risk factors for CRVO have been identified as increasing age, hypertension, diabetes, arteriosclerotic vascular risk factors (i.e., hyperlipidemia), and glaucoma.\textsuperscript{9} Although there are marked differences in the pathogenesis of each risk factor, it has been shown that subclinical inflammation with the production of reactive oxygen species is an early shared pathogenic step.\textsuperscript{21–31} Thus, even before clinically evident disease, inflammation and reactive oxygen species can cause direct damage to the endothelium and lead to capillary closure. Furthermore, the increased expression of adhesion molecules during inflammation causes leukostasis, which can cause physical obstruction of capillary lumens resulting in nonperfusion.\textsuperscript{32} Dehydration and hypercoagulability disorders, additional CRVO risk factors,\textsuperscript{6} may also lead to capillary nonperfusion. The subclinical nature of these changes preceding clinical disease may explain why the majority of our fellow eye subjects did not report any of the known risk factors for CRVO, yet had a history of nonischemic CRVO in 1 eye and decreased microvascular density in the fellow eye.

Decreased microvascular density observed in fellow eyes may be a predictor of increased risk of future occlusion. The same processes that cause damage to the microvascular endothelium may affect larger vessels, leading to injury accumulation in the central retinal vasculature and ultimately CRVO. Another possibility is an acute-on-chronic mechanism where the chronic subclinical development of capillary non-perfusion leads to local tissue hypoxia and an increase in the production of reactive factors, such as endothelin-1 (vasoconstriction) and vascular endothelial growth factor.
(vessel permeability).33 Fraenkl et al have proposed that elevated concentrations of these factors can lead to the clinical picture of CRVO— a functional constriction of the vein, edema, and hemorrhage.33

There are some noted limitations of this preliminary study besides the small sample size. Because increasing age is itself a risk factor for CRVO that may cause decreased microvascular density, we believe that it was appropriate to compare nonischemic CRVO fellow eye results with non–age-matched healthy controls in their 20s. However, future studies should include a larger sample size and control for age. Another limitation of this study was that the medical histories collected from all subjects were self-reported. Most of our nonischemic CRVO subjects reported having undergone an extensive workup for the reason of occlusion that was inconclusive. Future studies with larger sample sizes should include a more comprehensive collection of blood pressure history, hemoglobin A1c, and lipid panel trends. Another limitation of this study was that all of the nonischemic CRVO-affected eyes had undergone treatment with intravitreal bevacizumab. This treatment likely slowed or may have even reversed the natural course of microvascular disease, limiting our comparison of affected eye data with fellow and healthy eye data.

There were a few notable limitations in acquisition of conventional images. The fact that a number of the UWFFAs were not performed near the time of AOSLO FA limits any statement of sensitivity of this modality for detecting subclinical pathology. Also, because microperimetry was performed in most cases immediately after AOSLO FA, microperimetry sensitivity may have on average been lower because of temporary bleaching of retina by blue light used in AOSLO FA.

Future prospective studies of the retinal microvasculature may be able to more fully determine the role of these anatomic changes in the pathogenesis of venous occlusion. The ability to study these phenomena at the capillary level over time may provide many additional insights into microvascular changes that have previously been unavailable because of limitations of our clinical imaging tools.
Acknowledgments

The authors thank Richard Bavier for his assistance with AOSLO FA imaging and image processing.

Supported by Marrus Family Foundation, Bendheim-Lowenstein Family Foundation, Wise Family Foundation, RD & Linda Peters Foundation, Edith C. Blum Foundation, Chairman’s Research Fund of the New York Eye and Ear Infirmary of Mount Sinai, the Glaucoma Research Foundation, an unrestricted departmental grant from Research to Prevent Blindness, and National Institutes of Health grants P30EY001931 and UL1TR000055. A. Dubra is the recipient of a Career Development Award from Research to Prevent Blindness and a Career Award at the Scientific Interface from the Burroughs Wellcome Fund.

Footnotes

A. Dubra: US Patent No: 8,226,236: Code P (Patent). R. B. Rosen: Clarity: Code C (Consultant); Opticology: Code C (Consultant); OD–OS: Code C (Consultant); Allergan: Code C (Consultant); Carl Zeiss Meditec: Code C (Consultant); Optovue: Code C (Consultant); Advanced Cellular Technologies: Code C (Consultant). The other authors do not have any conflicting interests to disclose.

References


